Sign In
Buy KZIA
$10.95
-0.84 (-7.12%)
At Close: Jun 03, 2026
SYDNEY , Dec. 11, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development, announced that data from two abstracts will be presented at the San Antonio Brea
Company and FDA to meet in December to discuss potential pathways to registration of paxalisib in glioblastoma multiforme (GBM) Company updates to corporate presentation and participation in upcoming
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting
08:45am, Wednesday, 02'nd Oct 2024
Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial response (PR) Over two-thirds of the patients at maximum tolerated dose (MTD) achieved intracranial response which compares favo
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
08:30am, Monday, 23'rd Sep 2024
SYDNEY , Sept. 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER
07:30am, Thursday, 12'th Sep 2024
SYDNEY , Sept. 12, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an agreement has been executed with QIMR Be
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
07:00am, Wednesday, 31'st Jul 2024
Australian biotech company Kazia Therapeutics (NASDAQ: KZIA ) stock rocked the market after reporting encouraging results from a Phase II/III trial for its glioblastoma brain cancer therapy Paxalisib.
Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics
06:10am, Thursday, 25'th Jul 2024
Biotechnology stock traders, listen up! Do you like to roll the dice and take your chances on promising drug developers?
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
12:25pm, Friday, 12'th Jul 2024
Kazia (KZIA) surges after positive data from a phase II/III study on its lead pipeline drug in patients with glioblastoma. Based on this data, it plans to seek an accelerated nod from the FDA.
From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher
10:08am, Friday, 12'th Jul 2024
If you've read all the warnings and still want to jump into some of the top penny stocks to buy, focus on the key fundamentals. That includes its earnings numbers, business models, product pipelines a
KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains
12:31pm, Thursday, 11'th Jul 2024
Kazia Therapeutics (NASDAQ: KZIA ) stock is continuing to rally on Thursday after the company reported positive alongside clinical trial data yesterday. The Kazia Therapeutics clinical trial covered t
There's a very short window to bet against the dollar, says Goldman Sachs.
06:49am, Thursday, 11'th Jul 2024
Should inflation behave as economists expect, there may be a window — a very brief window — to bet against the U.S. dollar DXY. That's the conclusion of Karen Reichgott Fishman, senior currency st
Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment
12:24pm, Wednesday, 10'th Jul 2024
Kazia Therapeutics Limited KZIA released results on Wednesday from the GBM-AGILE Phase 2/3 study that included an evaluation of paxalisib versus standard of care (SOC) for patients with glioblastoma
Why Is Kazia Therapeutics (KZIA) Stock Up 300% Today?
11:57am, Wednesday, 10'th Jul 2024
Kazia Therapeutics (NASDAQ: KZIA ) stock is soaring higher on Wednesday after the oncology-focused biotechnology company provided results from a Phase II/III clinical trial. These results concern the
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma
07:30am, Wednesday, 10'th Jul 2024
GBM AGILE trial data shows clinically meaningful improvement in a prespecified secondary analysis for overall survival in paxalisib-treated, newly diagnosed unmethylated patients with glioblastoma SYD
KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER
08:15am, Thursday, 27'th Jun 2024
SYDNEY , June 27, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce the presentation of new data from its lead pr
